Freenome, Inc. FRNM

Nasdaq · oncology · unclear · EDGAR · Updated Nov 4, 2026

Freenome, Inc. (Nasdaq: FRNM) is an oncology diagnostics company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
SimpleScreen CRC (cfDNA blood test)	Colorectal cancer screening; FDA-approved July 2026, Abbott holds exclusive US commercial rights as standalone test	unclear	NA_NON_THERAPEUTIC
SimpleScreen Lung (laboratory-developed test)	Lung cancer screening, ages 50-80 with >=20 pack-year history; launched Oct 20, 2026 as LDT, not FDA reviewed	unclear	NA_NON_THERAPEUTIC
Multi-cancer / additional single-cancer tests (Personalized Cancer Detection pipeline)	Additional cancer indications	unclear	NA_NON_THERAPEUTIC

Oct 20, 2026
positive SimpleScreen Lung achieved 85% sensitivity at 50% specificity and 99.8% negative predictive value in an independent cohort of adults ages 50 to 80 with ≥20 pack-year smoking history.In an independent cohort of 172 lung cancer cases and 436 controls, the test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value (NPV). Filing
Jul 27, 2026
approval FDA approved SimpleScreen CRC blood-based CRC screening test; PREEMPT CRC showed 81.1% sensitivity for CRC and 90.4% specificity for advanced neoplasia; $100M milestone from Abbott triggered.Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, and Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved SimpleScreen™ CRC Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export